Global & Disaster Medicine

Medical countermeasures (MCMs) to treat patients with radiation-induced myelosuppression following a radiological/nuclear incident

FDA

MCMs to treat patients with radiation-induced myelosuppression following a radiological/nuclear incident (H-ARS)

Myelosuppression occurs when radiation damages the bone marrow. Suppression of the bone marrow blocks the production of blood cells. There are FDA-approved products that can help patients with H-ARS by facilitating recovery of bone marrow cells that develop into white blood cells, including neutrophils, which help fight off infections.

FDA-approved products that may be used to treat adult and pediatric patients acutely exposed to myelosuppressive doses of radiation, a condition known as Hematopoietic Syndrome of Acute Radiation Syndrome, or H-ARS:


Leave a Reply

Categories

Recent Posts

Archives

Admin